Quarterly report pursuant to Section 13 or 15(d)

Cancer Genetics, Inc. Merger (Details Narrative)

v3.21.2
Cancer Genetics, Inc. Merger (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 30, 2021
Aug. 21, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Mar. 31, 2021
Feb. 23, 2021
Dec. 31, 2020
Business Acquisition [Line Items]                  
Common Stock, Par or Stated Value Per Share                 $ 0.0001
Business Combination, Acquisition Related Costs     $ 165,000 $ 2,310,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable     2,859,000   2,859,000   $ 2,670,000    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     9,500,000   $ 9,500,000   $ 9,500,000    
Common Stock [Member]                  
Business Acquisition [Line Items]                  
Stock Issued During Period, Shares, New Issues         805,000        
Merger Agreement [Member] | StemoniX [Member]                  
Business Acquisition [Line Items]                  
Stock Issued During Period, Shares, New Issues 804,711                
Business Combination, Consideration Transferred $ 59,900,000                
Merger Agreement [Member] | StemoniX [Member] | Common Stock [Member]                  
Business Acquisition [Line Items]                  
Stock Issued During Period, Shares, New Issues 11,007,186                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 50,740,000                
Merger Agreement [Member] | StemoniX [Member] | Common Stock Warrants [Member]                  
Business Acquisition [Line Items]                  
Stock Issued During Period, Shares, New Issues 2,157,686                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 9,040,000.00                
Merger Agreement [Member] | StemoniX [Member] | Common Stock Options [Member]                  
Business Acquisition [Line Items]                  
Stock Issued During Period, Shares, New Issues 55,907                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value $ 139,000                
Merger Agreement [Member] | StemoniX [Member] | Holders [Member]                  
Business Acquisition [Line Items]                  
Stock Issued During Period, Shares, New Issues   17,977,544              
Common Stock, Par or Stated Value Per Share   $ 0.0001              
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award   891,780              
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit   $ 0.66              
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit   4.61              
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price   $ 1.46              
Merger Agreement [Member] | StemoniX [Member] | Investor [Member]                  
Business Acquisition [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award   143,890              
Shares Issued, Price Per Share   $ 5.9059           $ 5.9059  
Merger Agreement [Member] | StemoniX and Cancer Genetics Inc [Member]                  
Business Acquisition [Line Items]                  
Business Combination, Acquisition Related Costs     165,000 $ 0 $ 2,300,000        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable     20,000   20,000       $ 1,000,000.0
Merger Agreement [Member] | StemoniX and Cancer Genetics Inc [Member] | Trade Names [Member]                  
Business Acquisition [Line Items]                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     1,500,000   $ 1,500,000        
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life         10 years        
Merger Agreement [Member] | StemoniX and Cancer Genetics Inc [Member] | Customer Relationships [Member]                  
Business Acquisition [Line Items]                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     $ 8,000,000.0   $ 8,000,000.0        
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life         10 years        
[custom:RoyaltyPaymentPercentage]         100.00%        
[custom:RevenuePercentageDescription]         Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments.